Talia Muram

Talia Muram currently serves as Executive Director and Head of Translational Pathology at Daiichi Sankyo, Inc., a position held since April 2022. Prior to this role, Talia held several positions at Eli Lilly and Company from September 2012 to April 2022, including Executive Director - Translational Medicine Biomarker Leader for Late Phase Oncology, Senior Medical Advisor, and Medical Advisor. Talia's expertise in anatomic pathology includes leading the interpretation of immunohistochemical and H&E stained slides for late phase clinical trials and developing assays for novel biomarker identification. Talia's academic experience includes serving as Assistant Professor at Indiana University School of Medicine and Clinical Instructor at ARUP Laboratories. Talia's educational background includes a Doctor of Medicine from Indiana University School of Medicine and multiple fellowships in surgical and molecular genetic pathology.